Clinical trial · Interventional
Different Reversal Agents in Pediatric Day-case Cancer Surgery
Sugammadex Versus Neostigmine in Pediatric Day-case Cancer Surgery
NCT03996655CI-TRIAL-00039211unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to compare the efficacy of sugammadex and neostigmine on reversing neuromuscular blockers in pediatric patients undergoing outpatient surgical procedures.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Post-operative Residual Curarization | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neostigmine | Drug | — | UNRESOLVED |
| Sugammadex Injection [Bridion] | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group S
- description
- Sugammadex for reversal of steroidal neuromuscular blockers, intravenous injection ,2mg/kg
- interventionNames
- Drug: Sugammadex Injection [Bridion]
- type
- ACTIVE_COMPARATOR
- label
- Group N
- description
- Reversal of neuromuscular blockers, iv injection, 0.05 mg/kg
- interventionNames
- Drug: Neostigmine
Primary outcomes (1)
- measure
- Recovery time
- timeFrame
- time from reversal administration until TOF ratio reaches0.9%, ranging from 1 to 2.5 minutes, measured withThe train-of-four (TOF) equipment working with the nerve-muscle acceleromyometry principle (TOF Draeger Medical Systems, Inc.16 Electronic Avenue,
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥2 years and \< 18 years. * American society of anesthesiologists (ASA) status 1-3. * patients undergoing outpatient procedures Exclusion Criteria: * Known drug hypersensitivity.- * History of renal or hepatic failure. * Diseases of the neuromuscular junction. * history of malignant hyperthermia.
References
Publications (2)
- BACKGROUNDAmmar AS, Mahmoud KM, Kasemy ZA. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. Acta Anaesthesiol Scand. 2017 Apr;61(4):374-380. doi: 10.1111/aas.12868. Epub 2017 Feb 10. PMID 28185260
- BACKGROUNDMeretoja OA. Neuromuscular block and current treatment strategies for its reversal in children. Paediatr Anaesth. 2010 Jul;20(7):591-604. doi: 10.1111/j.1460-9592.2010.03335.x. PMID 20642658